Orixha’s LuncoLive (acronym for Lung Conservative Liquid Ventilation) platform ambitions to become a new standard for Critical Care healthcare professionals in helping them provide better care to their patients.
Similar to what happened with the introduction of Mechanical Ventilation a few decades ago and Extra-Corporeal Membrane Oxygenation more recently, LuncoLive is set to become, in the 2030’s, a new standard for Critical and Intensive Care Units.
Starting with ultra-rapid induction of therapeutic hypothermia, then with respiratory support for Acute Respiratory Distress, LuncoLive could save lives and improve outcomes in several clinical applications and settings.
Discovered in the 1960’s, Liquid Ventilation holds the principle to have the patient breathe a liquid rich in oxygen, rather than a gaz. This technology has been tried for respiratory support, lung lavage and induction of ultra-rapid hypothermia.
The LuncoLive platform adapts in real-time the regulation of breathable liquid volume and pressure in the patients lungs. This patient-centric adaptative approach guarantees the safety of the procedure while preserving the physiology of the lungs.
Out of Hospital Cardiac Arrest is a major Public Health issue. With an incidence of 6 for 10,000 in western countries and a survival rate around 10%, it kills more than 600,000 people every year in Europe and North America.
Among about a third is resuscitated successfully and transferred comatose but alive to Cardiac Arrest Centers and Intensive Care Units.
Unfortunately, around two-third of these initially resuscitated patients die in the hospital within a few hours from brain, heart or multi-organ failure, triggered by a massive systemic cytokine storm called Post Cardiac Arrest Syndrome. Consequently, survival rate with good neurological recovery from out of hospital cardiac arrest is under 10% in the western world. To date, the only way to reduce in-hospital mortality is to induce therapeutic hypothermia. This should be done as quickly as possible post the initial resuscitation, when the heart restarts thanks to a defibrillator and / or CPR. Therapeutic hypothermia works by protecting critical organs from the Post Cardiac Arrest Syndrome at a temperature of 32 – 33°C. As shown by academic teams working on cardiac arrest physiopathology, ultra-rapid hypothermia induction reduces the inflammatory cytokine storm and lowers the cellular metabolism of neurons and other critical organs. Consequently, it protects the brain, heart and kidneys from the Post Cardiac Arrest cytokine storm.
Lung Conservative Liquid Ventilation developed by Orixha uses the lungs as thermal bio-exchangers to adjust precisely and continuously the blood and body temperature throughout the hypothermia induction procedure that lasts around 30 minutes.
Due to the unique exchange surface of the lungs with the blood compartment, the cooling power and speed to reach therapeutic hypothermia are orders of magnitude greater than with current hypothermia devices.
By adapting the LuncoLive platform to Targeted Temperature Management, Orixha develops a disruptive medical device solely dedicated to ultra-rapid therapeutic hypothermia induction: Vent2Cool.
Vent2Cool stems from over a decade of academic research and will be the first clinical application of the LuncoLive technology. Experimentally, in Post Cardiac Arrest in-vivo models, Vent2Cool significantly improves survival outcomes by reducing drastically neurological sequels.
LuncoLive platform holds great promise as a new respiratory support option for patients with Acute Respiratory Distress Syndrome.
The Orixha team is working on the development of a new medical device to provide respiratory support while limiting the mechanical pro-inflammatory stress applied to the lungs with traditional mechanical ventilation. his future device, named Vent2Breathe is currently in its initial development phase.